• Miplyffa (arimoclomol), the first ever medication specifically approved for Niemann-Pick disease type C, is now available from Zevra Therapeutics (NASDAQ:ZVRA).
• The drug is approved for use in combination with Johnson & Johnson's (JNJ) Zavesca (miglustat) for the treatment of patients two years and older. Zavesca is approved for Gaucher disease.
• Miplyffa works by boosting the activation of the transcription factors EB (TFEB) and E3 (TFE3), leading to the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes.
• The U.S. FDA approved Miplyffa in September.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.